Declining ad rates close two CMPMedica titles

Share this article:
Declining ad rates close two CMPMedica titles
Declining ad rates close two CMPMedica titles
CMPMedica ceased to publish two of its titles – Infections in Medicine and AIDS Reader – due to a continuing decline in print advertising sales.

Early last week, the company announced “company-wide” layoffs that “touched every department,” according to Amy Erdman, CMPMedica's director of marketing, research and circulation. Erdman declined to put a number on the layoffs. An article in Folio put the number of layoffs at “nearly 30,” citing a source familiar with the cuts.

Despite the absence of print issues, both titles will continue to “maintain a digital presence,” said Erdman, adding that other areas of the business, including digital advertising, are seeing positive growth. Erdman said the company does not have any current plans to stop print publication of other CMPMedica titles, which include Psychiatric Times, The Journal of Respiratory Diseases, Physicians Practice, Oncology News International, and others.

CMPMedica is a division of United Business Media, which also owns PR Newswire, TechWeb, and other information trade services and distribution channels.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...